Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

被引：0
|
作者：
F. Guffanti
M F Alvisi
A. Anastasia
F. Ricci
M. Chiappa
A. Llop-Guevara
V. Serra
R. Fruscio
A. Degasperi
S. Nik-Zainal
M R Bani
M. Lupia
R. Giavazzi
E. Rulli
G. Damia
机构：
[1] Istituto di Ricerche Farmacologiche Mario Negri IRCCS,Laboratory of Molecular Pharmacology, Department of Oncology
[2] Istituto di Ricerche Farmacologiche Mario Negri IRCCS,Laboratory of Methodology for Clinical Research, Department of Oncology
[3] Istituto di Ricerche Farmacologiche Mario Negri IRCCS,Laboratory of Cancer Metastasis Therapeutics, Department of Oncology
[4] Vall d’Hebron Institute of Oncology,Experimental Therapeutics Group
[5] University of Milan Bicocca,Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, San Gerardo Hospital
[6] University of Cambridge,MRC Cancer Unit, Hutchison/MRC Research Centre
[7] Addenbrooke’s Hospital,Academic Laboratory of Medical Genetics, Lv 6 Addenbrooke’s Treatment Centre
[8] IEO,Unit of Gynecological Oncology Research
[9] European Institute of Oncology IRCCS,undefined
来源：
British Journal of Cancer | 2023年 / 128卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1405 / 1405
相关论文
共 50 条
  • [1] Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
    Guffanti, F.
    Alvisi, M. F.
    Anastasia, A.
    Ricci, F.
    Chiappa, M.
    Llop-Guevara, A.
    Serra, V
    Fruscio, R.
    Degasperi, A.
    Nik-Zainal, S.
    Bani, M. R.
    Lupia, M.
    Giavazzi, R.
    Rulli, E.
    Damia, G.
    BRITISH JOURNAL OF CANCER, 2022, 126 (01) : 120 - 128
  • [2] Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
    F. Guffanti
    M F Alvisi
    A. Anastasia
    F. Ricci
    M. Chiappa
    A. Llop-Guevara
    V. Serra
    R. Fruscio
    A. Degasperi
    S. Nik-Zainal
    M R Bani
    M. Lupia
    R. Giavazzi
    E. Rulli
    G. Damia
    British Journal of Cancer, 2022, 126 : 120 - 128
  • [3] Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts (vol 126, pg 122, 2022 )
    Guffanti, F.
    Alvisi, M. F.
    Anastasia, A.
    Ricci, F.
    Chiappa, M.
    Llop-Guevara, A.
    Serra, V.
    Fruscio, R.
    Degasperi, A.
    Nik-Zainal, S.
    Bani, M. R.
    Lupia, M.
    Giavazzi, R.
    Rulli, E.
    Damia, G.
    BRITISH JOURNAL OF CANCER, 2023, 128 (07) : 1405 - 1405
  • [4] RAD51 foci in patient-derived ovarian cancer organoids are associated with response to carboplatin and olaparib
    Compadre, Amanda
    van Biljon, Lillian
    Fashemi, Bisiayo
    Graham, Olivia
    Rodriguez, Jeimmy
    Lomonosova, Elena
    Blachut, Barbara
    Kuroki, Lindsay
    McCourt, Carolyn
    Hagemann, Andrea
    Thaker, Premal
    Massad, L.
    Powell, Matthew
    Mutch, David
    Fuh, Katherine
    Khabele, Dineo
    Mullen, Mary
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S308 - S309
  • [5] RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
    Compadre, Amanda J.
    van Biljon, Lillian N.
    Valentine, Mark C.
    Llop-Guevara, Alba
    Graham, Emily
    Fashemi, Bisiayo
    Herencia-Ropero, Andrea
    Kotnik, Emilee N.
    Cooper, Isaac
    Harrington, Shariska P.
    Kuroki, Lindsay M.
    McCourt, Carolyn K.
    Hagemann, Andrea R.
    Thaker, Premal H.
    Mutch, David G.
    Powell, Matthew A.
    Sun, Lulu
    Mosammaparast, Nima
    Serra, Violeta
    Zhao, Peinan
    Lomonosova, Elena
    Khabele, Dineo
    Mullen, Mary M.
    CLINICAL CANCER RESEARCH, 2023, 29 (13) : 2466 - 2479
  • [6] RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models
    Talens, Francien
    Teixeira, Vivian Oliviera Nunes
    Kok, Yannick P.
    Chen, Mengting
    Rosenberg, Efraim H.
    Debipersad, Rashmie
    Duiker, Evelien W.
    van den Tempel, Nathalie
    Janatova, Marketa
    Zemankova, Petra
    Nederlof, Petra M.
    Wisman, G. Bea A.
    Kleibl, Zdenek
    de Jong, Steven
    van Vugt, Marcel A. T. M.
    NAR CANCER, 2024, 6 (04):
  • [7] An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
    Shah, Monjri M.
    Dobbin, Zachary C.
    Nowsheen, Somaira
    Wielgos, Monica
    Katre, Ashwini A.
    Alvarez, Ronald D.
    Konstantinopoulos, Panagiotis A.
    Yang, Eddy S.
    Landen, Charles N.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 331 - 337
  • [8] BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models
    Guffanti, Federica
    Mengoli, Ilaria
    Alvisi, Maria Francesca
    Dellavedova, Giulia
    Giavazzi, Raffaella
    Fruscio, Robert
    Rulli, Eliana
    Damia, Giovanna
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Heterogeneous response to bevacizumab combined with chemotherapy in patient-derived ovarian cancer xenografts
    Decio, A.
    Cesca, M.
    Bizzaro, F.
    Bani, M. R.
    Giavazzi, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S176 - S176
  • [10] RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer
    Hoppe, Michal M.
    Tan, David S. P.
    Lim, Diana G. Z.
    Karnezis, Anthony
    Huntsman, David
    Steel, Jennifer
    Liu, Xinxue
    Paul, James
    Lewsley, Liz-Anne
    Siddiqui, Nadeem
    Brown, Robert
    Jeyasekharan, Anand D.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
12345